ArticleFrontiers in medicine2025
Investigating the neuroprotective effect of heparin in improving mitochondrial function in rats with cardiac arrest cardiopulmonary resuscitation based on transcriptome sequencing.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cardiac arrest (CA) and subsequent cardiopulmonary resuscitation (CPR) often lead to severe brain injury, primarily driven by mitochondrial dysfunction and ischemia-reperfusion injury. While heparin is a known anticoagulant, its potential neuroprotective role through mitochondrial regulation post cardiac arrest and cardiopulmonary resuscitation (CA-CPR) remains poorly understood. This study aimed to explore the brain-protective mechanisms of heparin, focusing on its effects on mitochondrial function using transcriptome sequencing in a rat model of asphyxial CA-CPR. Methods: Male Sprague-Dawley rats were randomized into three groups: Sham, CPR (Model), and CPR + Heparin (CPR + HP, 0.5 mg/kg IV upon CPR initiation). Neurological function was assessed using modified Neurological Severity Scores (mNSS) over 7 days. Hippocampal tissues were collected for transcriptome sequencing, qPCR validation, histological examination (HE staining), transmission electron microscopy (TEM), and biochemical assays (ATP and ROS levels). Bioinformatic analyses included differential gene expression, KEGG/GO enrichment, protein-protein interaction (PPI) networks, and ROC analysis. Results: Heparin treatment significantly improved neurological outcomes, reduced cerebral edema, and enhanced the 20-day survival rate (55% vs. 30% in CPR group, Conclusion: Heparin provided neuroprotection after CA-CPR by ameliorating mitochondrial dysfunction via multi-target regulation of key genes (Epsa1, Idh2, and Hif3a), enhancing energy metabolism, reducing oxidative stress, and inhibiting hyperactivated coagulation-inflammation cascades. These findings highlight heparin's potential as an adjunctive therapy for improving neurological outcomes post-resuscitation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.